Dongpingheng Capital Leads Angel Round in Tongnuokang Focused on Synthetic Lethality for Precision Oncology

Synnocare was founded in November 2021, guided by "unmet clinical needs," focusing on genomic vulnerability targets (such as synthetic lethality, chromosomal instability, and whole-genome duplication). It integrates original artificial intelligence and bio-data mining technologies, as well as high-throughput screening techniques, into every aspect of new drug development, including target discovery, molecular drug design, clinical trial design, and patient enrollment. At the same time, it combines deep insights into disease biology with efficient medicinal chemistry expertise to develop small-molecule innovative drugs with global value. The company's founder, Dr. Houxing Fan, has over a decade of experience in new drug research and development and specializes in the early discovery of small-molecule innovative drugs. The co-founders of the company include professors from prestigious universities and former pharmaceutical executives with extensive biological and clinical experience, forming a cross-disciplinary R&D team in medicinal chemistry, artificial intelligence, and tumor biology, dedicated to addressing precision diagnosis and treatment of cancer.

Dr. Fan Houxing, the founder of the companySaid: "We are very grateful to investors for their recognition of our team and platform. Synnocare always puts patients at the center, starts from unmet clinical needs, focuses on the development of difficult drug targets, independently builds an AI-based R&D platform, and is committed to the research and development of original small molecule new drugs with global intellectual property rights. We believe that our technology platform will continuously launch a product pipeline with global competitiveness, enabling the company's development to be continuous and robust, standing out in a highly competitive environment, and bringing new treatment options to patients worldwide."

Yuan Mengmeng, Investment Director of the Biomedical Division at Nanjing Dynamic Balance Investment & Management Co. Ltd.The company's R&D team consists of senior medicinal chemists, artificial intelligence experts, and cancer biology specialists. They not only possess extensive hands-on experience in new drug development but can also leverage AI technology to discover new targets. Tumor treatments based on synthetic lethality can accurately target cancer cells and precisely screen patients according to the genetic mutations in their cancer cells. In the future, synthetic lethality will undoubtedly play a significant role in the precise treatment of tumors.